(RTTNews) - 4D Molecular Therapeutics (FDMT) announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback